Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

The current diagnostic pathway is "lengthy, resource-intensive, and costly," the researchers noted. It starts with screening ...

New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in ...

For women with mixed urinary incontinence (MUI) who have not had success with conservative treatments, intradetrusor ...

New technologies have the potential to help bridge the medical skills training gap in LMICs. As we progress in this age of ...

"It feels like a difficult time to be in healthcare and try to deliver exceptional care because of the financial pressures on ...

But after hearing about this initiative, I started to ask myself, "Is this the right time to ask these questions? Is knowing ...

This second of four exclusive episodes explores whether sparsentan can leapfrog renin-angiotensin system (RAS) blockade and how emerging biomarkers may reshape management of IgA nephropathy. Nigwekar: ...

The FDA has rehired at least some workers tasked with releasing public records generated by the agency's regulatory ...